Roivant Sciences (ROIV) EBT Margin (2020 - 2026)
Roivant Sciences' (ROIV) quarterly EBT Margin came in at 12520.47% in Q4 2025, down 1029296.0% YoY from N/an in Q4 2024, and down 23.67% on a QoQ basis from 10123.74% in Q3 2025.
Roivant Sciences (ROIV) EBT Margin (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of EBT Margin data on file, last reported at 12520.47% in Q4 2025.
- Quarterly EBT Margin fell 1029296.0% year-over-year to 12520.47% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 5249.7% (down 1293691.0% YoY) and the FY2026 annual result came in at 3203.12%, down 85710.0% from the prior year.
- EBT Margin eased to 12520.47% in Q4 2025, from 10123.74% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 21751.34% in Q4 2023 to a low of 12520.47% in Q4 2025.
- A 5-year average of 3125.93% and a median of 2503.44% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin soared 2483540 bps — and 2024, when it slumped 2397885 bps.
- Tracing ROIV's EBT Margin over 5 years: stood at 1372.62% in 2021, then plunged by 125 bps to 3084.05% in 2022, then jumped by 805 bps to 21751.34% in 2023, then sank by 110 bps to 2227.51% in 2024, then tumbled by 462 bps to 12520.47% in 2025.
- The last three EBT Margin figures came in at 12520.47% (Q4 2025), 10123.74% (Q3 2025), and 12408.39% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -20,427.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20,427.46% |
| Dec 31, 2025 | -12,520.47% |
| Sep 30, 2025 | -10,123.74% |
| Jun 30, 2025 | -12,408.39% |
| Dec 31, 2024 | -2,227.51% |
| Sep 30, 2024 | -5,014.15% |
| Jun 30, 2024 | -245.81% |
| Dec 31, 2023 | 21,751.34% |
| Sep 30, 2023 | -6,617.49% |
| Jun 30, 2023 | -1,508.01% |
| Dec 31, 2022 | -3,084.05% |
| Sep 30, 2022 | -2,503.44% |
| Jun 30, 2022 | -8,098.75% |
| Dec 31, 2021 | -1,372.62% |
| Sep 30, 2021 | -1,610.35% |
| Jun 30, 2021 | -1,305.56% |
| Dec 31, 2020 | -4,796.89% |
| Sep 30, 2020 | -3,989.95% |
| Jun 30, 2020 | -428.68% |